Joerg Huwyler
Hoffmann-La Roche
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joerg Huwyler.
Bioorganic & Medicinal Chemistry Letters | 2010
Patrizio Mattei; Markus Boehringer; Patrick Di Giorgio; Holger Fischer; Michael Hennig; Joerg Huwyler; Buelent Kocer; Bernd Kuhn; Bernd Michael Loeffler; Alexander Macdonald; Robert Narquizian; Etienne Rauber; Elena Sebokova; Urs Sprecher
Design, synthesis, and SAR are described for a class of DPP-IV inhibitors based on aminobenzo[a]quinolizines with non-aromatic substituents in the S1 specificity pocket. One representative thereof, carmegliptin (8p), was chosen for clinical development. Its X-ray structure in complex with the enzyme and early efficacy data in animal models of type 2 diabetes are also presented.
Bioorganic & Medicinal Chemistry Letters | 2010
Thomas Johannes Woltering; Juergen Wichmann; Erwin Goetschi; Frédéric Knoflach; Theresa M. Ballard; Joerg Huwyler; Silvia Gatti
This study completes a series of papers devoted to the characterization of the non-competitive mGluR2/3 antagonist properties of 1,3-dihydro-benzo[b][1,4]diazepin-2-one derivatives with particular emphasis on derivatizations compatible with brain penetration and in vivo activity. Especially the compounds bearing a para-pyridine consistently showed in vivo activity in rat behavioral models after oral administration, for example, blockade of the mGluR2/3 agonist LY354740-induced hypoactivity and improvement of a working memory deficit induced either by LY354740 or scopolamine in the delayed match to position task (DMTP). Moreover, combination studies with a cholinesterase inhibitor show apparent synergistic effects on working memory impairment induced by scopolamine.
Bioorganic & Medicinal Chemistry Letters | 2010
Markus Boehringer; Holger Fischer; Michael Hennig; Daniel Hunziker; Joerg Huwyler; Bernd Kuhn; Bernd Michael Loeffler; Thomas Luebbers; Patrizio Mattei; Robert Narquizian; Elena Sebokova; Urs Sprecher; Hans Peter Wessel
Synthesis and SAR are described for a structurally distinct class of DPP-IV inhibitors based on aminobenzo[a]quinolizines bearing (hetero-)aromatic substituents in the S1 specificity pocket. The m-(fluoromethyl)-phenyl derivative (S,S,S)-2g possesses the best fit in the S1 pocket. However, (S,S,S)-2i, bearing a more hydrophilic 5-methyl-pyridin-2-yl residue as substituent for the S1 pocket, displays excellent in vivo activity and superior drug-like properties.
Journal of Pharmacology and Experimental Therapeutics | 2000
Andrew J. Grottick; Gerhard Trube; William A. Corrigall; Joerg Huwyler; Parichehr Malherbe; Rene Wyler; Guy A. Higgins
Neuropharmacology | 2003
Guy A. Higgins; Theresa M. Ballard; Joerg Huwyler; John A. Kemp; Rammy Gill
Bioorganic & Medicinal Chemistry Letters | 2005
Eric Vieira; Joerg Huwyler; Synese Jolidon; Frédéric Knoflach; Vincent Mutel; Juergen Wichmann
Archive | 2001
Alexander Alanine; Bernd Buettelmann; Holger Fisher; Neidhart Marie-Paule Heitz; Joerg Huwyler; Georg Jaeschke; Emmanuel Pinard; Rene Wyler
Archive | 2003
Joerg Huwyler; Frédéric Knoflach; Eric Vieira; Juergen Wichmann
Archive | 2002
Joerg Huwyler; Roland Jakob-Roetne; Sonia Maria Poli
Archive | 2006
Anton Haselbeck; Frank Herting; Joerg Huwyler; Michael Jarsch